Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So assuming that I got that right, we’re certainly very excited about our pending data update on the Phase 2 study coming up in the first half of this year |
| So we were very pleased to have reported on the additional positive safety and efficacy results from our completed global pivotal Phase 3 trial in WHIM in May of last year and further analyses of the trial at several important medical meetings and congresses both last year and earlier this year |
| Additionally, we’ve experienced strong engagement with our What If It’s WHIM Disease Awareness Campaign, which is also demonstrating an even broader interest in WHIM syndrome |
| With our successful Phase 3 WHIM trial recently being presented at major medical conferences, we are very encouraged that the physician community is now gaining more awareness |
| We look forward to leveraging our rare disease commercial capabilities to start building the WHIM market over time, with 2024 as the year to lay the foundation for future success and looking beyond 2024 as we are successful in educating physicians, helping them identify WHIM patients and build demand for our product candidate |
| As we look ahead to 2024, we thought we’d take the time to reflect on all that we’ve accomplished over the past year, milestones that have set the stage for what we expect will be an incredibly exciting and truly transformative year for X4, a year where we aim to become a fully integrated research, development and commercialization company with the goal of delivering new options for rare disease patients |
| I mention this not only to emphasize the incredible burden of disease for these patients and their caregivers, but also to highlight that mavorixafor has been granted breakthrough therapy designation by the FDA, indicating their recognition of mavorixafor as a product candidate with the potential to provide substantial improvement over the standard-of-care in the treatment, diagnosis or prevention of a serious condition |
| Both of her presentations were extremely well attended, as was our What If It’s WHIM booth, all of which served to increase our visibility and enable what we believe can result in a major leap forward for patients through physician awareness and education |
| Really getting excited for the launch here |
| Now turning to our chronic neutropenia program, we were able to make significant progress in advancing mavorixafor and CN during 2023 as well |
| I mean, I think, what the field has been sharing with us is just the general excitement because the data are so strong with an oral once daily |
| As you know, the Phase 3 trial successfully met its primary endpoint and several key secondary endpoints with participants on mavorixafor achieving statistically significant elevations in both their neutrophil and lymphocyte counts versus placebo, and importantly, statistically significant reductions in the rate of annualized infections and clinically meaningful reductions in the severity and duration of infections versus placebo |
| Although our Phase 2 clinical trial was a little slower to enroll than we’d initially expected, we were able to learn and increase enrollment and achieve our target of at least 15 patients by early November and we continue to expect to announce additional Phase 2 results in the 15 plus trial participants in the coming months |
| We have a countdown clock on the wall as our expected PDUFA date and we could not be more energized to know that we are so close to potentially achieving our vision of delivering meaningful benefits to those with rare diseases of the immune system by gaining approval for what would be the first and only targeted therapy for the treatment of people with WHIM syndrome |
| Our commercial and medical affairs organizations have grown meaningfully, although prudently, as we’ve continued to build our brand marketing and sales infrastructure to increase our presence at medical meetings and engage with our targeted hematologists and immunologists that we expect to have WHIM patients under their care |
| And as Paula said, we’re really building the foundations for a launch that enables the product to get to patients as quickly as possible |
| I’ve seen your team at a lot of these medical conferences, so great work getting the community aware of what’s going on there |
| We’re also pleased to report that at the recent Quad AI Immunology Meeting in late February, not only was our abstract on the lymphocyte subset data from our four WHIM trial accepted as an oral presentation by Dr |
| Given mavorixafor’s rare pediatric disease designation, we are optimistic that we’ll receive a priority review voucher, which can be used for a subsequent application or sold to another drug sponsor should mavorixafor be approved |
| We appreciate all the attention and insightful questions and wish you an enjoyable rest of your day |
| Good luck |
| As you can well appreciate, we’ve been incredibly busy preparing for this potential approval since we spoke with you last year |
| We’ve had productive interactions with regulators in Europe and now believe we may be able to submit for EMA approval in late 2024, early 2025 |
| Of course, in our first three patients, we saw a nice durable elevation in patients with combination GCSF |
| Great |
| Importantly, all of the preliminary data presented to-date and other learnings from the Phase 2 trial, along with our interactions with the FDA, have enabled us to finalize the protocol for a global, pivotal, Phase 3 clinical trial of mavorixafor and CN, and advance the initiation of this important next trial in the first half of 2024 |
| His presentation was enthusiastically welcomed by a standing room only audience |
| Good morning |
| Good morning |
| Good morning |
| Statement |
|---|
| Given its rarity and lack of available therapies, disease awareness amongst our targeted physician audience has historically been quite low, with no approved treatments for WHIM and only supportive care for symptomatic management, not addressing the underlying cause of the disease |
| Unfortunately, this drug is so challenging to take and to manage that physicians and patients stay on the very low end, sometimes as low as 20% of base of the labeled dose |
| Finally, we reported a net loss of $19.1 million and $101.2 million for the fourth quarter and full year ended December 31st, compared to $29.1 million and $93.9 million for the comparable periods in 2022 |
| Over time, WHIM patients with recurrent infections may experience debilitating and life-threatening complications, including increased cancer risk, irreversible end organ damage and/or sepsis |
| It’s a very poorly educated disease |
| The most challenging burden faced by people with WHIM syndrome results from their low blood levels of neutrophils or neutropenia and low blood levels of lymphocytes or lymphopenia, which research supports are experienced by essentially all WHIM patients |
| Net losses included $2.5 million and $8.7 million of stock-based compensation expenses for the fourth quarter and full year 2023, respectively, compared to $1.1 million and $5.2 million for the comparable periods in 2022 |
| Christophe Arbet-Engels, gave a talk on the lack of innovation and the need for new treatments at the meeting |
Please consider a small donation if you think this website provides you with relevant information